- Home
- PRAX vs RELY Comparison
PRAX vs RELY Comparison
Compare PRAX & RELY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- RELY
- Stock Information
- Founded
- PRAX 2015
- RELY 2011
- Country
- PRAX United States
- RELY United States
- Employees
- PRAX N/A
- RELY N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- RELY Computer Software: Prepackaged Software
- Sector
- PRAX Health Care
- RELY Technology
- Exchange
- PRAX Nasdaq
- RELY Nasdaq
- Market Cap
- PRAX 4.0B
- RELY 3.8B
- IPO Year
- PRAX 2020
- RELY 2021
- Fundamental
- Price
- PRAX $178.75
- RELY $16.95
- Analyst Decision
- PRAX Strong Buy
- RELY Buy
- Analyst Count
- PRAX 13
- RELY 11
- Target Price
- PRAX $202.85
- RELY $26.18
- AVG Volume (30 Days)
- PRAX 1.4M
- RELY 2.7M
- Earning Date
- PRAX 11-07-2025
- RELY 11-05-2025
- Dividend Yield
- PRAX N/A
- RELY N/A
- EPS Growth
- PRAX N/A
- RELY N/A
- EPS
- PRAX N/A
- RELY 0.06
- Revenue
- PRAX $7,765,000.00
- RELY $1,461,898,000.00
- Revenue This Year
- PRAX N/A
- RELY $30.78
- Revenue Next Year
- PRAX $20.00
- RELY $20.69
- P/E Ratio
- PRAX N/A
- RELY $269.54
- Revenue Growth
- PRAX 338.45
- RELY 35.12
- 52 Week Low
- PRAX $26.70
- RELY $14.28
- 52 Week High
- PRAX $205.89
- RELY $27.32
- Technical
- Relative Strength Index (RSI)
- PRAX 80.27
- RELY 57.80
- Support Level
- PRAX $164.75
- RELY $15.20
- Resistance Level
- PRAX $192.96
- RELY $16.13
- Average True Range (ATR)
- PRAX 11.99
- RELY 0.45
- MACD
- PRAX 13.57
- RELY 0.25
- Stochastic Oscillator
- PRAX 82.53
- RELY 95.10
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About RELY Remitly Global Inc.
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.